While ramping up to begin clinical trials with its recombinant Factor IX product for hemophilia B, Inspiration Biopharmaceuticals Inc. entered a $35 million collaboration with Celtic Pharmaceutical Holdings LP. (BioWorld Today)
While ramping up to begin clinical trials with its recombinant Factor IX product for hemophilia B, Inspiration Biopharmaceuticals Inc. entered a $35 million collaboration with Celtic Pharmaceutical Holdings LP. (BioWorld Today)
An auction process for the drug began in August, but Isis Chairman, President and CEO Stanley Crooke told BioWorld Today he started laying the groundwork long before that. (BioWorld Today)
An auction process for the drug began in August, but Isis Chairman, President and CEO Stanley Crooke told BioWorld Today he started laying the groundwork long before that. (BioWorld Today)
Tacere Therapeutics Inc. teamed up with Pfizer Inc. to develop and commercialize TT-033, a preclinical hepatitis C drug consisting of three short-hairpin RNAs (shRNAs) delivered within an adeno-associated virus (AAV) protein coat. (BioWorld Today)
Tacere Therapeutics Inc. teamed up with Pfizer Inc. to develop and commercialize TT-033, a preclinical hepatitis C drug consisting of three short-hairpin RNAs (shRNAs) delivered within an adeno-associated virus (AAV) protein coat. (BioWorld Today)
